Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: Advantages and limitations

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 1, 1997, Pages 63-68

  Weiss, Arthur J ^a,b   Lackman, Richard D ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Chemotherapy Doxorubicin Ifosphamide Sarcomas; Concurrent use of G CSF

Indexed keywords

CISPLATIN; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINATE CALCIUM; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DOSE RESPONSE; DRUG EFFICACY; EWING SARCOMA; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUBULE ACIDOSIS; LEUKOPENIA; MALE; OSTEOSARCOMA; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CLINICAL TRIALS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOXURIDINE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; IFOSFAMIDE; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; MALE; SARCOMA;

EID: 0031013264     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199702000-00014     Document Type: Article

References (30)

1. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-508.
2. Broxmeyer HE, Benninger L, Patel S, et al. Differences in kinetic response of human marrow myeloid progenitor cells to in vivo treatment of G-CSF vs GM-CSF. Blood 1992;80:287A.
3. Minderman H, Linssen PCM, Wessels JMC, et al. Doxorubicin toxicity in relation to the proliferative state of human hematopoietic cells. Exp Hematol 1991;19:110-4.
4. Cannistra SA, Groshek P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989;3:328-34.
5. Bunn PA, Crowley J, Hazuka M, et al. The role of GM-CSF in limited stage SCLC: A randomized phase III study of the Southwest Oncology Group. [Abstract] Proc Am Soc Clin Oncol 1992;11:292.
6. Carlson RH. GM-CSF causes thrombocytopenia in breast cancer trial. Oncology Times May 1992, p1.
7. Miller LL. Current status of G-CSF in support of chemotherapy and radiotherapy. Oncology 1993;10:67-88.
8. Weiss AJ, Lackman RD. Dose intensification by the simultaneous use of rhG-CSF and anti-cancer chemotherapy. Int J Oncol 1995;6:329-32.
9. Bronchud MH, Howell A, Crowther D, et al. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989;60:121-5.
10. Elias AD, Eder JP, Shea T, et al. High dose ifosphamide with mesna uroprotection: A phase I study. J Clin Oncol 1990;8: 170-8.
11. Meropol NJ, Miller LL, Korn EL, et al. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992;84:1201-3.
12. Rowinsky E, Sartorius S, Grochow L, et al. Phase I and pharmacologic study of topetecan an inhibitor of topoisomerase I with granulocyte colony-stimulating factor: Toxicologic differences between concurrent and post-treatment G-CSF administration. [Abstract] Proc Am Soc Clin Oncol 1992;11:116.
13. Pret A, Kantarjian H. Management of adult acute lymphocytic leukemia; present issues and key challenges. J Clin Oncol 1994;126:1312-22.
14. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80:1430-6.
15. Ohno R, Tomonaga M, Ohshima T, et al. A randomized controlled study of granulocyted colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Int J Hematol 1993;58:73-81.
16. Stahel RA, Muller E, Pichert G, et al. Dose intensification with autologous marrow support in high-risk lymphoma: acceleration of hematopoietic recovery and reduction of days of hospitalization with granulocyte colony-stimulating factor-(G-CSF) in a randomized open-label trial [Abstract]. Proc Am Soc Clin Oncol 1992;11:331.
17. Ohno R, Hiraoka A, Tanimoto M, et al. No increase of leukemia relapse in newly diagnosed acute myeloid leukemia who received granulocyte colony-stimulating factor (G-CSF) for life threatening infection during induction and consolidation therapy [Abstract]. Proc Am Assoc Cancer Res 1993;34:197.
18. Gianni AM, Bregni M, Siena S, et al. Recombinant human granulocyte macrophage colony stimulating factor reduces hematologic toxicity and ones clinical ability of high dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990;10:768-78.
19. Manara MC, Scotlandi K, Serra M, et al. Absence of stimulatory effect of G-CSF on the growth of human sarcoma cells. Int J Oncol 1995;6:1011-4.
20. Seidman AD, Scher HI, Gabrilove JL, et al. Dose-intensificadon of MVAC with recombinant granulocyte colony stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 1993;11:408-14.
21. Loehrer PJ, Elson P, Dreicer AL. A phase I-II study of escalating doses of methotrexate, vinblastine, doxorubicin, cisplatinol and RHG-CSF in advanced urothelial cancer, NECOG trial. [Abstract] Proc Am Soc Clin oncol 1992;11:201.
22. Hudis C, Lebwohl D, Crown J, et al. Feasibility of adjuvant dose-intensive cyclophosphamide (C) with G-CSF after doxorubicin (A) in women (pts) with high-risk stage II/III resectable breast cancer (BC) [Abstract]. Proc Am Soc Clin Oncol 1992;11:55.
23. Brachman D, Haraf D, Weichselbaum R, et al. Granulocyte-colony stimulating factor (G-CSF) and concomitant accelerated chemotherapy for advanced head and neck cancer (hnc): a dose escalation study. [Abstract] Proc Am Soc Clin Oncol 1993;12:280.
24. Gabrilove JL, Jakubowski A, Fain K. Phase I study of granulocyte colony-stimulating factors in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988;82:1454-61.
25. Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small lung cancer. Br J Cancer 1987;56:809-13.
26. Eguchi K, Shinkai T, Sasaki Y, et al. Subcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy for patients with advanced lung cancer. Jpn J Cancer Res 1990;81:1168-74.
27. Sarosy G, Cohen E, Stone D, et al. Phase I Study of taxol and granulocyte colony stimulating factoring patients with ovarian cancer. J Clin Oncol 1992;10:1165-70.
28. Edmonson JH. Needed: qualitative improvement in antisarcoma therapy [Editorial]. J Clin Oncol 1995;13:1531-3.
29. Edmonson J, Long H, Kvols L. Cytotoxic drugs plus subcutaneous granulocyte-macrophage colony-stimulating factor: can molgramostim enhance antisarcoma therapy? J Natl Cancer Inst (Ltr) 1994;85:312.
30. Oken MM, Creech RH, Tormey DC, et al. Toxicity and responce criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.